PDX1 and pancreatic neoplasm: In addition, the intraperitoneal administration of the inhibitor EHT5372 in Pdx-1-cre LSL/KrasG12D/Ink4a/Arf null B6 mice, a mouse model of pancreatic cancer, resulted in maintenance of their viability for up to 8 weeks, whereas the control mice showed only 30% survival by 8 weeks.